Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of ...

Diseases of the joints are known as arthritis. The term is derived from the Greek word that means exactly that: diseases of ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...

If you suffer from psoriasis, cooler weather could be bad news. Learn how high and low humidity levels can affect psoriasis ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

In the trials, a significantly greater proportion of Sotyktu -treated patients achieved ACR20 response (at least a 20 percent improvement in signs ... said, "Psoriatic arthritis is a heterogenous ...

Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

Psoriasis is a common, chronic inflammatory dermatosis, and patients with psoriasis often develop nail involvement. It is ...

These seven blue-chip dividend stocks provide investors a steady stream of passive income and offer promising total return.